Extended results from the COURAGE and ISCHEMIA trials revealed that an invasive strategy did not provide improved outcomes for patients with stable coronary artery disease over a 25-year period.
Key Clinical Findings
The COURAGE trial, with a median follow-up of 15 years, demonstrated no diverging event curves between patients receiving an initial invasive strategy and those receiving optimal medical therapy. Similarly, the ISCHEMIA trial, with a median follow-up of 11 years, showed no significant difference in all-cause mortality or combined events between invasive and conservative management groups. The ISCHEMIA-CKD trial, extending the study to patients with chronic kidney disease, also found no benefit from an upfront invasive strategy.
Trial Characteristics
The high rate of repeat revascularization was observed in patients receiving PCI. The findings support a conservative initial approach in most cases of chronic stable coronary artery disease, with shared decision-making guiding treatment based on individual patient characteristics. The COURAGE trial included 959 participants with a mean age of 62.7 years, while ISCHEMIA included 5,179 participants with a mean age of 64 years. Both trials highlighted the importance of ongoing guideline-directed medical therapy and careful monitoring.